Lilly To Build $6B Pharmaceutical Manufacturing Facility In Alabama
Eli Lilly and Company announced Tuesday, Dec. 9 plans to invest more than $6 billion in a new manufacturing facility in Huntsville, Ala.
Read MoreTag Archives: GLP-1
Lilly Announces Changing The Thread Collection Campaign
Eli Lilly and Co. has launched a national campaign aimed at reducing the stigma surrounding obesity, using personal stories and visual symbolism to highlight the challenges faced by people living with the disease.
Read More
Lilly To Offer Direct-To-Employer Programs
Eli Lilly and Co. is preparing a new direct-to-employer model that will allow companies to offer coverage for its obesity medications, including Zepbound, beginning in early 2026.
Read MoreEli Lilly Becomes First Pharmaceutical To Hit $1 Trillion Valuation
Eli Lilly and Co. on Friday, Nov. 21 became the first health care company to surpass a $1 trillion market valuation, driven by intense investor demand for its fast-growing weight-loss drug portfolio.
Read More
Eli Lilly To Build $3B Netherlands Manufacturing Facility
Indianapolis-based Eli Lilly and Company announced Monday, Nov. 3 that it plans to build a new $3 billion manufacturing facility in Katwijk, the Netherlands, located within the Leiden Bio Science Park.
Read MoreLilly Announces $1.2B Puerto Rico Expansion, Adding 100 Jobs
Eli Lilly and Company announced Wednesday, Oct. 29 a planned investment of more than $1.2 billion to expand and modernize its Lilly del Caribe manufacturing site in Carolina, Puerto Rico.
Read MoreLilly Shares Slide Following Weight Loss Pill Trial Results
Indianapolis-based Eli Lilly and Co. shares fell Thursday, Aug. 7 following the pharmaceutical company’s second-quarter earnings report, alongside results from a closely watched trial of its experimental weight-loss pill.
Read MoreLilly Downplaying Obesity Drug Side Effects, Indiana Lawsuits Claim
Lawsuits from at least 26 patients have been filed in Marion County against Eli Lilly and Co. for its marketing of the drugs GLP-1 Trulicity and Mounjaro, claiming the treatments for diabetes and obesity had adverse side effects that the company downplayed or did not mention in advertising.
Read More
New Weight-Loss Drug Announces Positive Results of Human Adipose Tissue Study
Adipo Therapeutics, LLC, a late pre-clinical biopharmaceutical company developing treatments for obesity and related metabolic disorders, announced the positive results for a key study demonstrating promising results using human tissue samples.
Read More